Abstract:Despite effective new therapies, adaptive resistance remains the main obstacle in acute myelogenous leukemia (AML) therapy. Autophagy induction is a key mechanism for adaptive resistance. Leukemic blasts at diagnosis express higher levels of the apical autophagy kinase ULK1 compared with normal hematopoietic cells. Exposure to chemotherapy and targeted agents upregulate ULK1, hence we hypothesize that developing ULK1 inhibitors may present the unique opportunity for clinical translation of autophagy inhibition. Accordingly, we demonstrate that ULK1 inhibition, by genetic and pharmacologic means, suppresses treatment-induced autophagy, overcomes adaptive drug-resistance, and synergizes with chemotherapy and emerging antileukemia agents like venetoclax (ABT-199). The study next aims at exploring the underlying mechanisms. Mechanistically, ULK1 inhibition downregulates MCL1 antiapoptotic gene, impairs mitochondrial function and downregulates components of the CD44-xCT system, resulting in impaired reactive oxygen species (ROS) mitigation, DNA damage, and apoptosis. For further validation, several mouse models of AML were generated. In these mouse models, ULK1 deficiency impaired leukemic cell homing and engraftment, delayed disease progression, and improved survival. Therefore, in the study, we validated our hypothesis and identified ULK1 as an important mediator of adaptive resistance to therapy and an ideal candidate for combination therapy in AML. Therefore, we propose ULK1 inhibition as a therapeutically relevant treatment option to overcome adaptive drug-resistance in AML. Implications: ULK1 drives a cell-intrinsic adaptive resistance in AML and targeting ULK1-mediated autophagy can synergize with existing and emerging AML therapies to overcome drug-resistance and induce apoptosis.

A patent review of UNC-51-like kinase 1/2 inhibitors (2019–present)

The mechanism of UNC-51-like kinase 1 and the applications of small molecule modulators in cancer treatment

An updated patent review of Akt inhibitors (2016-present)

An updated patent review of AKT inhibitors (2020 - present)

Physiological functions of ULK1/2

Development of potent and selective ULK1/2 inhibitors based on 7-azaindole scaffold with favorable in vivo properties

Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo

ULK1 as a therapeutic target in kidney diseases: Current perspective

Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present)

Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

Discovery of human autophagy initiation kinase ULK1 inhibitors by multi-directional in silico screening strategies

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia

Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer

Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)

Development of small-molecule inhibitors that target PI3Kβ

Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 - 2019)

A patent review of RAF kinase inhibitors (2010-2018).

Review of research on dual PI3K-mTOR small molecular inhibitors

Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy

Substituted indole derivatives as UNC-51-like kinase 1 inhibitors: Design, synthesis and anti-hepatocellular carcinoma activity